Ticlopidine-induced acute cholestatic hepatitis

被引:14
|
作者
Wegmann, C
Munzenmaier, R
Dormann, AJ
Huchzermeyer, H
机构
[1] Klinikum Minden, Med Klin, D-32427 Minden, Germany
[2] Klinikum Minden, Inst Pathol, D-32427 Minden, Germany
关键词
D O I
10.1055/s-2007-1023919
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
History and admission findings: A 52-year-old man who had sustained a cerebellar infarct was given the platelet inhibitor ticlopidine (2 x 250 mg/d) to prevent further thromboses. 28 days after starting the medication he complained of itchings, feeling unwell and diarrhoea. He had also noted darkened urine and faecal discoloration, Physical examination revealed marked jaundice and multiple scratch marks over the entire body. Investigations: The activities in serum of alkaline phosphatase (420 U/I) and of gamma-GT (470 U/I) were markedly elevated and total bilirubin concentration was maximally 26.4 mg/dl. Activities of GPT (197 U/I) and GOT (44 U/I) were slightly increased. No cause was found for any extra-or intrahepatic cholestasis with or without mechanical obstruction (e. g. viral or autoimmune hepatitis). A biopsy, which showed centro-acinar cholestasis also suggested drug-induced liver damage. Treatment and course: Despite discontinuing ticlopidine, the signs of cholestatic hepatitis had only disappeared 2 1/2 months after the onset of symptoms. Conclusion: Changes in the blood picture, allergic skin reactions and gastrointestinal disorders are among the significant clinical side effects of ticlopidine. As this drug is increasingly being prescribed world-wide, the possibility of toxic liver damage should be taken into account.
引用
收藏
页码:146 / 150
页数:5
相关论文
共 50 条
  • [31] Cholestatic hepatitis: Ticlopidine suspected
    Roy, L
    Plante, MA
    Perreault, H
    Biron, P
    THERAPIE, 1995, 50 (06): : 593 - 594
  • [32] TICLOPIDINE-INDUCED PROLONGED CHOLESTASIS
    NURHUSSEIN, MA
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1993, 41 (12) : 1371 - 1372
  • [33] TICLOPIDINE-INDUCED PROLONGED CHOLESTASIS
    NASCHITZ, JE
    KHAMESSI, R
    ELIAS, N
    YESHURUN, D
    JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 1995, 33 (04): : 379 - 380
  • [34] Ticlopidine-induced thrombotic thrombocytopenic purpura
    Muszkat, M
    Shapira, MY
    Sviri, S
    Linton, DM
    Caraco, Y
    PHARMACOTHERAPY, 1998, 18 (06): : 1352 - 1355
  • [35] Ticlopidine-induced lupus with renal involvement
    Ohtake, Takayasu
    Kobayashi, Shuzo
    Okamoto, Koji
    Oka, Machiko
    Maesato, Kyoko
    Yasu, Takeo
    Moriya, Hidekazu
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (07) : 1992 - 1993
  • [36] Clopidogrel treatment in a patient with ticlopidine-induced hepatitis following percutaneous coronary stenting
    Anselmino, M.
    Moretti, C.
    Ravera, L.
    Sheiban, I.
    MINERVA CARDIOANGIOLOGICA, 2010, 58 (02): : 277 - 280
  • [37] Ticlopidine-induced elevated liver enzymes
    Klepser, TB
    Jogerst, GJ
    PHARMACOTHERAPY, 1997, 17 (04): : 819 - 821
  • [38] Reduced multidrug resistance-associated protein 2 in ticlopidine-induced cholestatic liver injury
    Gabbi, Chiara
    Bertolotti, Marco
    DIGESTIVE AND LIVER DISEASE, 2020, 52 (02) : 236 - 238
  • [39] Ticlopidine-associated cholestatic hepatitis
    Adams, L
    Jeffrey, GP
    Deboer, B
    Garas, G
    INTERNAL MEDICINE JOURNAL, 2002, 32 (07) : 359 - 360
  • [40] Cholestatic hepatitis due to a therapy with ticlopidine
    Berent, R
    Hinterholzer, G
    Höbling, W
    Auer, J
    Haidenthaler, A
    Knoflach, P
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2000, 38 (07): : 587 - 591